Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
7.30
Ask:
7.50
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Bleepa builds on robust data management security

19 Jan 2021 07:00

RNS Number : 0946M
Feedback PLC
19 January 2021
 

REACH

 

Feedback plc

 

Bleepa builds on robust data management security

 

· Cyber Essentials Plus Certified

· ISO 27001 compliant

 

London, 19 January 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces it has bolstered its data management security with certification of Cyber Essentials Plus and ISO 27001 for its flagship imaging-based communication platform, Bleepa. The enhanced data management protection will provide customers and clinicians with added confidence in the safety of Bleepa's data security.

 

Bleepa, a secure instant messaging platform which facilitates the sharing of clinical grade medical images between personal devices, is an essential tool to enable remote and secure communications between clinicians and their teams. Security of data is of the utmost importance for remote communications and Feedback continuously reviews and updates its security to comply with international standards.

 

The Cyber Essentials Plus audit is a UK Government backed scheme to enable organisations to guard against a whole range of the most common cyber-attacks and demonstrates a commitment to cyber security.

 

ISO 27001 is the international standard that sets out the specification for an information security management system (ISMS). Its best-practice approach helps organisations manage their information security by addressing people and processes as well as technology.

 

Both certificates are sought by the Company's healthcare customers and will bolster customer confidence in the security of the Bleepa platform.

 

Dr Tom Oakley, CEO of Feedback, commented:

 

"Feedback seeks to liberate frontline clinicians from inadequate, cumbersome operational systems by safely simplifying how they communicate with each other and how they access information about patients, most notably medical imaging. The emphasis here is on safety. As a medical device manufacturer, we already adhere to stringent quality processes that comply with ISO 13485, however, being a digital medical device brings new challenges to safety and quality that are not reflected in traditional medical device certification. We have sought to address these challenges and demonstrate our commitment to data security as rigorously as the processes which we apply to ensuring quality. Cyber Essentials Plus and ISO 27001 confirm the security of Bleepa as a platform just as ISO 13485 confirms the quality and safety of its manufacture. This combined certification is testament to our commitment to providing clinicians with the right tools for the job and will give customers confidence about the security of data on the platform."

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0) 20 3997 7634

IR@fbk.com

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

 

Notes to editors

 

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

 

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABPMLTMTIBBBB
Date   Source Headline
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement
20th Apr 20157:00 amRNSAdoption of TexRAD research software
13th Apr 20157:00 amRNSCollaboration with the Oxford Stone Group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.